Update on COX-2 inhibitor patents with a focus on optimised formulation and therapeutic scope of drug combinations making use of COX-2 inhibitors

Expert Opinion on Therapeutic Patents

Volumn 16, Issue 4, 2006, Pages 403-430

  Puhlmann, Ulrike ^a   Schäfer, Dirk ^b,c   Ziemann, Christina ^d  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b SIAT GmbH   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

Author keywords

Cancer; COX 2; Drug combination; Inflammation; Pain; Rheumatic disease

Indexed keywords

5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; BETA CYCLODEXTRIN; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIPYRONE; ETORICOXIB; FLURBIPROFEN; GABRILEN; IBUPROFEN; IDOMETHINE KOWA; INDOMETACIN; KETOPROFEN; KETOTOP L; LICOFELONE; LUMIRACOXIB; MELOXICAM; NAPROXEN; NIMESULIDE; NITRONAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PARECOXIB; PHENACETIN; PHENAZONE; ROFECOXIB; THROMBOXANE A2; UNINDEXED DRUG; VALDECOXIB;

ACUTE KIDNEY FAILURE; ADENOMATOUS POLYP; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFUSION; DEPRESSION; DIGESTIVE SYSTEM ULCER; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SOLUBILITY; DRUG STRUCTURE; FRACTURE NONUNION; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; GENITAL SYSTEM DISEASE; HALLUCINATION; HEALING IMPAIRMENT; HEART INFARCTION; HUMAN; HYPERTENSION; INSOMNIA; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; LIVER DISEASE; MEMBRANOUS GLOMERULONEPHRITIS; NONHUMAN; OSTEOARTHRITIS; PERIPHERAL EDEMA; PROTEIN FUNCTION; PSYCHOPATHY; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN MANIFESTATION; SODIUM RETENTION; SOMNOLENCE; STROKE; THROMBOEMBOLISM; URINARY EXCRETION;

EID: 33645768088     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.16.4.403     Document Type: Review

References (187)

1. HIGGS GA, VANE JR: Inhibition of cyclooxygenase and lipoxygenase. Br. Med. Bull. (1983) 39(3):265-270.
2. VANE JR, BOTTING RM: Mechanism of action of nonsteroidal anti-inflammatory drugs. Am. J. Med. (1998) 104(3A):2S-8S.
3. VANE JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. (1971) 231(25):232-235.
4. SMITH JB, WILLIS AL: Aspirin selectively inhibits prostaglandin production in human platelets. Nat. New Biol. (1971) 231(25):235-237.
5. FERREIRA SH, MONCADA S, VANE JR: Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat. New Biol. (1971) 231(25):237-239.
6. FU JY, MASFERRER JI, SEIBERT K, RAZ A, NEEDLEMAN P: The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J. Biol. Chem. (1990) 265(28):16737-16740.
7. KUJUBU DA, FLETCHER BS, VARNUM BC, LIM RW, HERSCHMAN HR: TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem. (1991) 266(20):12866-12872.
8. MASFERRER JL, ZWEIFEL BS, SEIBERT K, NEEDLEMAN P: Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J. Clin. Invest. (1990) 86(4):1375-1379.
9. MASFERRER JL, SEIBERT K, ZWEIFEL B, NEEDLEMAN P: Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc. Natl. Acad. Sci. USA (1992) 89(9):3917-3921.
10. MASFERRER JL, SEIBERT K: Regulation of prostaglandin synthesis by glucocorticoids. Receptor (1994) 4(1):25-30.
11. HLA T, NEILSON K: Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. USA (1992) 89(16):7384-7388.
12. HERSCHMAN HR: Prostaglandin synthase 2. Biochim. Biophys. Acta (1996) 1299(1):125-140.
13. O'BANION MK, SADOWSKI HB, WINN V, YOUNG DA: A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J. Biol. Chem. (1991) 266(34):23261-23267.
14. O'BANION MK, WINN VD, YOUNG DA: cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc. Natl. Acad. Sci. USA (1992) 89(11):4888-4892.
15. DUBOIS RN, ABRAMSON SB, CROFFORD L et al.: Cyclooxygenase in biology and disease. FASEB J. (1998) 12(12):1063-1073.
16. FOSSLIEN E: Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit. Rev. Clin. Lab Sci. (2000) 37(5):431-502.
17. LEVY GN: Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer. FASEB J. (1997) 11(4):234-247.
18. PATRIGNANI P, PANARA MR, SCIULLI MG et al.: Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal antiinflammatory drugs. J. Physiol Pharmacol. (1997) 48(4):623-631.
19. BRIDEAU C, KARGMAN S, LIU S et al.: A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenasc inhibitors. Inflamm. Res. (1996) 45(2):68-74.
20. HARRIS RC, BREYER MD: Physiological regulation of cyclooxygenasc-2 in the kidney. Am. J. Physiol. Renal Physiol. (2001) 281(1): F1-F11.
21. ZIMMERMANN KC, SARBIA M, SCHROR K, WEBER AA: Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Mol. Pharmacol. (1998) 54(3):536-540.
22. BAENKLER HW, ZEUS J, SCHENK J, SCHAFER D: Abnormal eicosanoid pattern by blood leukocytes in gastroduodenal ulcer. Med. Sci. Monit. (2004) 10(10):CR557-CR562.
23. SCHAFER D, LINDENTHAL U, WAGNER M, BOLCSKEI PL, BAENKLER HW: Effect of prostaglandin E2 on eicosanoid release by human bronchial biopsy specimens from normal and inflamed mucosa. Thorax (1996) 51(9):919-923.
24. THERLAND KL, STUBBE J, THIESSON HC et al.: Cycloxygenase-2 is expressed in vasculature of normal and ischemic adult human kidney and is colocalized with vascular prostaglandin E2: EP4 receptors. J. Am. Soc. Nephrol. (2004) 15(5):1189-1198.
25. BOMBARDIER C, LAINE L, REICIN A et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. (2000) 343(21):1520-1528.
26. JUNI P, DIEPPE P, EGGER M: Risk of myocardial infarction associated with selective COX-2 inhibitors: questions remain. Arch. Intern. Med. (2002) 162(22):2639-2640.
27. MUKHERJEE D, NISSEN SE, TOPOL EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA (2001) 286(8):954-959.
28. CHENEVARD R, HURLIMANN D, BECHIR M et al.: Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation (2003) 107(3):405-409.
29. SUDBO J, LEE JJ, LIPPMAN SM et al.: Non-steroidal anti-inflammatory drugs and the risk of oral cancer: a nested case-control study. Lancet (2005) 366(9494):1359-1366.
30. GARAVITO RM, DEWITT DL: The cyclooxygenase isoforms: structural insights into the conversion of arachidonic acid to prostaglandins. Biochim. Biophys. Acta (1999) 1441(2-3):278-287.
31. SMITH WL, GARAVITO RM, DEWITT DL: Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J. Biol. Chem. (1996) 271(52):33157-33160.
32. HWANG D, SCOLLARD D, BYRNE J, LEVINE E: Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J. Natl. Cancer Inst. (1998) 90(6):455-460.
33. O'NEILL GP, FORD-HUTCHINSON AW: Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett. (1993) 330(2):156-160.
34. YAMAGATA K, ANDREASSON KI, KAUFMANN WE, BARNES CA, WORLEY PF: Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron (1993) 11(2):371-386.
35. YASOJIMA K, SCHWAB C, MCGEER EG, MCGEER PL: Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res. (1999) 830(2):226-236.
36. HARRIS RC, BREYER MD: Physiological regulation of cyclooxygenase-2 in the kidney. Am. J. Physiol. Renal Physiol. (2001) 281(1):F1-F11.
37. OHNO R, YOSHINAGA K, FUJITA T et al.: Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma. Cancer (2001) 91(10):1876-1881.
38. TOKUYAMA O, NAKAMURA Y, MUSO A et al.: Expression and distribution of cyclooxygenase-2 in human periovulatory ovary. Int. J. Mol. Med. (2001) 8(6):603-606.
39. KUJUBU DA, FLETCHER BS, VARNUM BC, LIM RW, HERSCHMAN HR: TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem. (1991) 266(20):12866-12872.
40. GARAVITO RM, DEWITT DL: The cyclooxygenase isoforms: structural insights into the conversion of arachidonic acid to prostaglandins. Biochim. Biophys. Acta (1999) 1441(2-3):278-287.
41. HINZ B, BRUNE K: [COX-1 and COX-2: functions and pharmacological effects]. Pharm. Unserer Zeit (1999) 28(1):21-29.
42. MICHAUX C, CHARLIER C: Structural approach for COX-2 inhibition. Mini. Rev. Med. Chem. (2004) 4(6):603-615.
43. KURUMBAIL RG, STEVENS AM, GIERSE JK et al.: Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature (1996) 384(6610):644-648.
44. CHANDRASEKHARAN NV, DAI H, ROOS KL et al.: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Natl. Acad. Sci. USA (2002) 99(21):13926-13931.
45. FLOWER RJ, VANE JR: Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature (1972) 240(5381):410-411.
46. SIMMONS DL, BOTTING RM, ROBERTSON PM, MADSEN ML, VANE JR: Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs. Proc. Natl. Acad. Sci. USA (1999) 96(6):3275-3280.
47. QIN N, ZHANG SP, REITZ TL, MEI JM, FLORES CM: Cloning, expression and functional characterization of human COX-1 splicing variants: evidence for intron 1 retention. J. Pharmacol. Exp. Ther. (2005).
48. BOTTING R: COX-1 and COX-3 inhibitors. Thromb. Res. (2003) 110(5-6):269-272.
49. SIMMONS DL: Variants of cyclooxygenase-1 and their roles in medicine. Thromb. Res. (2003) 110(5-6):265-268.
50. KIS B, SNIPES JA, BUSIJA DW: Acetaminophen and the COX-3 puzzle: sorting out facts, fictions and uncertainties. J. Pharmacol. Exp. Ther. (2005).
51. BUTTAR NS, WANG KK: The 'aspirin' of the new millennium: cyclooxygenase-2 inhibitors. Mayo Clin. Proc. (2000) 75(10):1027-1038.
52. CHUNG S: Profiles of COX-2 inhibitors: present and future. Expert Opin. Ther. Patents (2005) 15(1):9-32.
53. DANNHARDT G, LAUFER S: Structural approaches to explain the selectivity of COX-2 inhibitors: is there a common pharmacophore? Curr. Med. Chem. (2000) 7(11):1101-1112.
54. DANNHARDT G, KIEFER W: Cyclooxygenase inhibitors - current status and future prospects. Eur. J. Med. Chem. (2001) 36(2):109-126.
55. GANS KR, GALBRAITH W, ROMAN RJ et al.: Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J. Pharmacol. Exp. Ther. (1990) 254(1):180-187.
56. SUPURAN CT, CASINI A, MASTROLORENZO A, SCOZZAFAVA A: COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents. Mini. Rev. Med. Chem. (2004) 4(6):625-632.
57. WEBER A, CASINI A, HEINE A et al.: Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J. Med. Chem. (2004) 47(3):550-557.
58. DI FIORE A, PEDONE C, D'AMBROSIO K et al.: Carbonic anhydrase inhibitors: valdecoxib binds to a different active site region of the human isoforin II as compared to the structurally related cyclooxygenase II 'selective' inhibitor celecoxib. Bioorg. Med. Chem. Lett. (2006) 16(2):437-442.
59. WALTER MF, JACOB RF, DAY CA et al.: Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis (2004) 177(2):235-243.
60. SCHNITZER TJ, BURMESTER GR, MYSLER E et al.: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet (2004) 364(9435):665-674.
61. CHUNG S: COX-2 inhibitors with a methylsulfoxide pharmacophore. Expert Opin. Ther. Patents (2005) 15(5):617-620.
62. WALLACE JL, DEL SOLDATO P: The therapeutic potential of NO-NSAIDs. Fundam. Clin. Pharmacol. (2003) 17(1):11-20.
63. MACNAUGHTON WK, CIRINO G, WALLACE JL: Endothelium-derived relaxing factor (nitric oxide) has protective actions in the stomach. Life Sci. (1989) 45(20):1869-1876.
64. KITAGAWA H, TAKEDA F, KOHEI H: Effect of endothelium-derived relaxing factor on the gastric lesion induced by HCl in rats. J. Pharmacol. Exp. Ther. (1990) 253(3):1133-1137.
65. WALLACE JL, REUTER B, CICALA C et al.: Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology (1994) 107(1):173-179.
66. CSONT T, FERDINANDY P: Cardioprotective effects of glyceryl trinitrate: beyond vascular nitrate tolerance. Pharmacol. Ther. (2005) 105(1):57-68.
67. HAWKEY CJ, JONES JI, ATHERTON CT et al.: Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Gut (2003) 52(11):1537-1542.
68. MUSCARA MN, LOVREN F, MCKNIGHT W et al.: Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats. Br. J. Pharmacol. (2001) 133(8):1314-1322.
69. ENGELHARDT G, BOGEL R, SCHNITZER C, UTZMANN R: Meloxicam: influence on arachidonic acid metabolism. Part 1. In vitro findings. Biochem. Pharmacol. (1996) 51(1):21-28.
70. NOBLE S, BALFOUR JA: Meloxicam. Drugs (1996) 51(3):424-430.
71. LAZER ES, MIAO CK, CYWIN CL et al.: Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity. J. Med. Chem. (1997) 40(6):980-989.
72. BAENKLER HW, SCHAFER D, HOSEMANN W: Eicosanoids from biopsy of normal and polypous nasal mucosa. Rhinology (1996) 34(3):166-170.
73. SCHAFER D, SCHMID M, GODE UC, BAENKLER HW: Dynamics of eicosanoids in peripheral blood cells during bronchial provocation in aspirin-intolerant asthmatics. Eur. Respir. J. (1999) 13(3):638-646.
74. O'BYRNE PM, ISRAEL E, DRAZEN JM: Antileukotrienes in the treatment of asthma. Ann. Intern. Med. (1997) 127(6):472-480.
75. WENZEL SE, KAMADA AK: Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma. Ann. Pharmacother. (1996) 30(7-8):858-864.
76. TSUJI F, OKI K, FUJISAWA K et al.: Involvement of leukotriene B4 in arthritis models. Life Sci. (1999) 64(3):L51-L56.
77. POMMERY N, TAVERNE T, TELLIEZ A et al.: New COX-2/5-LOX inhibitors: apoptosis-inducing agents potentially useful in prostate cancer chemotherapy. J. Med. Chem. (2004) 47(25):6195-6206.
78. MANEV R, MANEV H: 5-Lipoxygenase as a putative mechanism of NSAID-related psychiatric adverse events. Drugs (2005) 65(4):577.
79. GAY RE, NEIDHART M, PATAKY F et al.: Dual inhibition of 5-lipoxygenase and cyclooxygenases 1 and 2 by ML3000 reduces joint destruction in adjuvant arthritis. J. Rheumatol. (2001) 28(9):2060-2065.
80. BOILEAU C, PELLETIER JP, TARDIF G et al.: The regulation of human MMP-13 by licofelone, an inhibitor of cyclooxygenases and 5-lipoxygenase, in human osteoarthritic chondrocytes is mediated by the inhibition of the p38 MAP kinase signalling pathway. Ann. Rheum. Dis. (2005) 64(6):891-898.
81. PELLETIER JP, BOILEAU C, BOILY M et al.: The protective effect of licofelone on experimental osteoarthritis is correlated with the downregulation of gene expression and protein synthesis of several major cartilage catabolic factors: MMP-13, cathepsin K and aggrecanases. Arthritis Res. Ther. (2005) 7(5):R1091-R1102.
82. MOREAU M, DAMINET S, MARTEL-PELLETIER J, FERNANDES J, PELLETIER JP: Superiority of the gastroduodenal safety profile of licofelone over rofecoxib, a COX-2 selective inhibitor, in dogs. J. Vet. Pharmacol. Ther. (2005) 28(1):81-86.
83. SMOLKA AJ, GOLDENRING JR, GUPTA S, HAMMOND CE: Inhibition of gastric H,K-ATPase activity and gastric epithelial cell IL-8 secretion by the pyrrolizine derivative ML 3000. BMC Gastroenterol. (2004) 4:4.
84. BAUDUIN P, RENONCOURT A, KOPF A, TOURAUD D, KUNZ W: Unified concept of solubilization in water by hydrotropes and cosolvents. Langmuir (2005) 21(15):6769-6775.
85. JAWITZ JW, DAI D, RAO PS, ANNABLE MD, RHUE RD: Rate-limited solubilization of multicomponent nonaqueous-phase liquids by flushing with cosolvents and surfactants: modeling data from laboratory and field experiments. Environ. Sci. Technol. (2003) 37(9):1983-1991.
86. MILLARD J, ALVAREZ-NUNEZ F, YALKOWSKY S: Solubilization by cosolvents. Establishing useful constants for the log-linear model. Int. J. Pharm. (2002) 245(1-2):153-166.
87. RAN Y, ZHAO L, XU Q, YALKOWSKY SH: Solubilization of cyclosporin A. AAPS PharmSciTech. (2001) 2(1):E2.
88. ZHAO L, LI P, YALKOWSKY SH: Solubilization of fluasterone. J. Pharm. Sci. (1999) 88(10):967-969.
89. SUBRAMANIAN N, RAY S, GHOSAL SK, BHADRA R, MOULIK SP: Formulation design of self-microemulsifying drug delivery systems for improved oral bioavailability of celecoxib. Biol. Pharm. Bull. (2004) 27(12):1993-1999.
90. RAWAT S, JAIN SK: Solubility enhancement of celecoxib using β-cyclodextrin inclusion complexes. Eur. J. Pharm. Biopharm. (2004) 57(2):263-267.
91. CHANG RK, SHOJAEI AH: Effect of hydroxypropyl β-cyclodextrin on drug solubility in water-propylene glycol mixtures. Drug Dev. Ind. Pharm. (2004) 30(3):297-302.
92. DOLLO G, LE CORRE P, CHOLLET M et al.: Improvement in solubility and dissolution rate of 1,2-dithiole-3-thiones upon complexation with β-cyclodextrin and its hydroxypropyl and sulfobutyl ether-7 derivatives. J. Pharm. Sci. (1999) 88(9):889-895.
93. TIRUCHERAI GS, MITRA AK: Effect of hydroxypropyl β-cyclodextrin complexation on aqueous solubility, stability, and corneal permeation of acyl ester prodrugs of ganciclovir. AAPS PharmSciTech. (2003) 4(3):E45.
94. TALLEY JJ, BROWN DL, CARTER JS et al.: 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J. Med. Chem. (2000) 43(5):775-777.
95. TALLEY JJ, BERTENSHAW SR, BROWN DL et al.: N-[[(5-Methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: a potent and selective inhibitor of COX-2 for parenteral administration. J. Med. Chem. (2000) 43(9):1661-1663.
96. NUSSMEIER NA, WHELTON AA, BROWN MT et al.: Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med. (2005) 352(11):1081-1091.
97. LOFTSSON T, BREWSTER ME: Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. (1996) 85(10):1017-1025.
98. BOOKMAN AA, WILLIAMS KS, SHAINHOUSE JZ: Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial. CMAJ. (2004) 171(4):333-338.
99. MASON L, MOORE RA, EDWARDS JE, DERRY S, MCQUAY HJ: Topical NSAIDs for acute pain: a meta-analysis. BMC. Fam. Pract. (2004) 5(1):10.
100. GASPARINI G, LONGO R, SARMIENTO R, MORABITO A: Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol. (2003) 4(10):605-615.
101. SUBBARAMAIAH K, DANNENBERG AJ: Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol. Sci. (2003) 24(2):96-102.
102. ELDER DJ, BAKER JA, BANU NA, MOORGHEN M, PARASKEVA C: Human colorectal adenomas demonstrate a size-dependent increase in epithelial cyclooxygenase-2 expression. J. Pathol. (2002) 198(4):428-434.
103. ZHANG H, SUN XF: Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am. J. Gastroenterol. (2002) 97(4):1037-1041.
104. SHIRAHAMA T, SAKAKURA C: Overexpression of cyclooxygenase-2 in squamous cell carcinoma of the urinary bladder. Clin. Cancer Res. (2001) 7(3):558-561.
105. DENKERT C, WINZER KJ, MULLER BM et al.: Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer (2003) 97(12):2978-2987.
106. KOGA H, SAKISAKA S, OHISHI M et al.: Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology (1999) 29(3):688-696.
107. TANG TC, POON RT, LAU CP, XIE D, FAN ST: Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma. World J. Gastroenterol. (2005) 11(13):1896-1902.
108. FANG HY, LIN TS, LIN JP et al.: Cyclooxygenase-2 in human non-small cell lung cancer. Eur. J. Surg. Oncol. (2003) 29(2):171-177.
109. WATKINS DN, LENZO JC, SEGAL A, GARLEPP MJ, THOMPSON PJ: Expression and localization of cyclooxygenase isoforms in non-small cell lung cancer. Eur. Respir. J. (1999) 14(2):412-418.
110. YUAN A, YU CJ, SHUN CT et al.: Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. Int. J. Cancer (2005) 115(4):545-555.
111. NAKANISHI Y, KAMIJO R, TAKIZAWA K, HATORI M, NAGUMO M: Inhibitors of cyclooxygenase-2 (COX-2) suppressed the proliferation and differentiation of human leukaemia cell lines. Eur. J. Cancer (2001) 37(12):1570-1578.
112. CHOY H, MILAS L: Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance?. J. Natl. Cancer Inst. (2003) 95(19):1440-1452.
113. KISHI K, PETERSEN S, PETERSEN C et al.: Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res. (2000) 60(5):1326-1331.
114. NAKATA E, MASON KA, HUNTER N et al.: Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors. Int. J. Radiat. Oncol. Biol. Phys. (2004) 58(2):369-375.
115. PETERSEN C, PETERSEN S, MILAS L, LANG FF, TOFILON PJ: Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clin. Cancer Res. (2000) 6(6):2513-2520.
116. KOMAKI R, LIAO Z, MILAS L: Improvement strategies for molecular targeting: cyclooxygenase-2 inhibitors as radiosensitizers for non-small cell lung cancer. Semin. Oncol. (2004) 31(1, Suppl. 1):47-53.
117. LIAO Z, KOMAKI R, MILAS L et al.: A Phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Clin. Cancer Res. (2005) 11(9):3342-3348.
118. CERCHIETTI LC, BONOMI MR, NAVIGANTE AH et al.: Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases. J. Neurooncol. (2005) 71(1):73-81.
119. REARDON DA, QUINN JA, VREDENBURGH J et al.: Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer (2005) 103(2):329-338.
120. TAKETO MM: Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J. Natl. Cancer Inst. (1998) 90(20):1529-1536.
121. TAKETO MM: Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J. Natl. Cancer Inst. (1998) 90(21):1609-1620.
122. ZHA S, YEGNASUBRAMANIAN V, NELSON WG, ISAACS WB, DE MARZO AM: Cyclooxygenases in cancer: progress and perspective. Cancer Lett. (2004) 215(1):1-20.
123. NO AUTHORS LISTED: Carbonic anhydrase/COX-2 inhibitors in the treatment of various diseases. Expert Opin. Ther. Patents (2004) 14(12):1803-1806.
124. MENDELSOHN J, BASELGA J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. (2003) 21(14):2787-2799.
125. CHOE MS, ZHANG X, SHIN HJ, SHIN DM, CHEN ZG: Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol. Cancer Ther. (2005) 4(9):1448-1455.
126. ABDELRAHIM M, SAFE S: Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins. Mol. Pharmacol. (2005) 68(2):317-329.
127. GATELY S, LI WW. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin. Oncol. (2004) 31(2, Suppl.7):2-11.
128. BAGULEY BC: Antivascular therapy of cancer: DMXAA. Lancet Oncol. (2003) 4(3):141-148.
129. ZHAO L, CHING LM, KESTELL P, KELLAND LR, BAGULEY BC: Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): increased tumor vascular permeability. Int. J. Cancer (2005) 116(2):322-326.
130. ZHOU S, KESTELL P, BAGULEY BC, PAXTON JW: 5,6-Dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy. Invest. New Drugs (2002) 20(3):281-295.
131. ZHAO Y, AGARWAL VR, MENDELSON CR, SIMPSON ER: Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology (1996) 137(12):5739-5742.
132. BUNDRED NJ, BARNES NL: Potential use of COX-2-aromatase inhibitor combinations in breast cancer. Br. J. Cancer (2005) 93(Suppl.1):S10-S15.
133. JOENSUU H, EJLERTSEN B, LONNING PE, RUTQVIST LE: Aromarase inhibitors in the treatment of early and advanced breast cancer. Acta Oncol. (2005) 44(1):23-31.
134. KUDACHADKAR R, O'REGAN RM: Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer. CA Cancer J. Clin. (2005) 55(3):145-163.
135. SOROKIN A: Cyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phenotype. Curr. Pharm. Des. (2004) 10(6):647-657.
136. SUROWIAK P, MATERNA V, MATKOWSKI R et al.: Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance. Breast Cancer Res. (2005) 7(5):R862-R870.
137. NARDONE G, ROCCO A, VAIRA D et al.: Expression of COX-2, mPGE-synthase1, MDR-1 (P-gp), and Bcl-xL: a molecular pathway of H. pylori-related gastric carcinogenesis. J. Pathol. (2004) 202(3):305-312.
138. KIM SK, LIM SY, WANG KC et al.: Overexpression of cyclooxygenase-2 in childhood ependymomas: role of COX-2 inhibitor in growth and multi-drug resistance in vitro. Oncol. Rep. (2004) 12(2):403-409.
139. PUHLMANN U, ZIEMANN C, RUEDELL G et al.: Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells. J. Pharmacol. Exp. Ther. (2005) 312(1):346-354.
140. ZIEMANN C, SCHAFER D, RUDELL G, KAHL GF, HIRSCH-ERNST KI: The cyclooxygenase system participates in functional mdr1b overexpression in primary rat hepatocyte cultures. Hepatology (2002) 35(3):579-588.
141. GHIELMINI M, COLLI E, BOSSHARD G et al.: Hematotoxicity on human bone marrow- and umbilical cord blood-derived progenitor cells and in vitro therapeutic index of methoxymorpholinyldoxorubicin and its metabolites. Cancer Chemother. Pharmacol. (1998) 42(3):235-240.
142. QUINTIERI L, GERONI C, FANTIN M et al.: Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes. Can. Cancer Res. (2005) 11(4):1608-1617.
143. STEINGART AB, COTTERCHIO M: Do antidepressants cause, promote, or inhibit cancers? J. Clin. Epidemiol. (1995) 48(11):1407-1412.
144. PEER D, DEKEL Y, MELIKHOV D, MARGALIT R: Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res. (2004) 64(20):7562-7569.
145. FORTE LR: Guanylin regulatory peptides: structures, biological activities mediated by cyclic GMP and pathobiology. Regul. Pept. (1999) 81(1-3):25-39.
146. FORTE LR JR: Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics. Pharmacol. Ther. (2004) 104(2):137-162.
147. PITARI GM, DI GUGLIELMO MD, PARK J, SCHULZ S, WALDMAN SA: Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells. Proc. Natl. Acad. Sci. USA (2001) 98(14):7846-7851.
148. SHAILUBHAI K, YU HH, KARUNANANDAA K et al.: Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP. Cancer Res. (2000) 60(18):5151-5157.
149. KIEFER W, DANNHARDT G: COX-2 inhibition and the control of pain. Curr. Opin. Investig. Drugs (2002) 3(9):1348-1358.
150. MA W, EISENACH JC: Morphological and pharmacological evidence for the role of peripheral prostaglandins in the pathogenesis of neuropathic pain. Eur. J. Neurosci. (2002) 15(6):1037-1047.
151. CARR DB, GOUDAS LC: Acute pain. Lancet (1999) 353(9169):2051-2058.
152. MCCLESKEY EW, GOLD MS: Ion channels of nociception. Ann. Rev. Physiol (1999) 61:835-856.
153. WOOLF CJ: Windup and central sensitization are not equivalent. Pain (1996) 66(2-3):105-108.
154. MAXWELL T: Cancer pain management in the elderly. Geriatr. Nurs. (2000) 21(3):158-163.
155. TURAN A, EMET S, KARAMANLIOGLU B et al.: Analgesic effects of rofecoxib in ear-nose-throat surgery. Anesth. Analg. (2002) 95(5):1308-1311.
156. TANG J, LI S, WHITE PF et al.: Effect of parecoxib, a novel intravenous cyclooxygenase type-2 inhibitor, on the postoperative opioid requirement and quality of pain control. Anesthesiology (2002) 96(6):1305-1309.
157. FRIDE E, MECHOULAM R: Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur. J. Pharmacol. (1993) 231(2):313-314.
158. WALKER JM, HUANG SM, STRANGMAN NM, TSOU K, SANUDO-PENA MC: Pain modulation by release of the endogenous cannabinoid anandamide. Proc. Natl. Acad. Sci. USA (1999) 96(21):12198-12203.
159. CRAVATT BF, LICHTMAN AH: Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr. Opin. Chem. Biol. (2003) 7(4):469-475.
160. DEUTSCH DG, UEDA N, YAMAMOTO S: The fatty acid amide hydrolase (FAAH). Prostaglandins Leukot. Essent. Fatty Acids (2002) 66(2-3):201-210.
161. 1A receptors in the descending anti-nociceptive pathway from periaqueductal gray to the spinal dorsal horn in intact rats, rats with nerve injury and rats with inflammation. Neuroscience (2002) 112(2):399-407.
162. 1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease. Neurosci. Res. (2005) 52(2):185-194.
163. FEINBERG SD: Prescribing analgesics. How to improve function and avoid toxicity when treating chronic pain. Geriatrics (2000) 55(11):44-53.
164. CIEZA A, STUCKI G: Understanding functioning, disability, and health in rheumatoid arthritis: the basis for rehabilitation care. Curr. Opin. Rheumatol. (2005) 17(2):183-189.
165. TARNER IH, HARLE P, MULLER-LADNER U, GAY RE, GAY S: The different stages of synovitis: acute versus chronic, early versus late and non-erosive versus erosive. Best. Pract. Res. Clin. Rheumatol. (2005) 19(1):19-35.
166. SMOLEN JS, ALETAHA D, MACHOLD KP: Therapeutic strategies in early rheumatoid arthritis. Best. Pract. Res. Clin. Rheumatol. (2005) 19(1):163-177.
167. KATZ WA: Cyclooxygenase-2-selective inhibitors in the management of acute and perioperative pain. Cleve. Clin. J. Med. (2002) 69(Suppl.1):SI65-SI75.
168. MOY FJ, CHANDA PK, CHEN JM et al.: High-resolution solution structure of the catalytic fragment of human collagenase-3 (MMP-13) complexed with a hydroxamic acid inhibitor. J. Mol. Biol. (2000) 302(3):671-689.
169. BLAGG JA, NOE MC, WOLF-GOUVEIA LA et al.: Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14. Bioorg. Med. Chem. Lett. (2005) 15(7):1807-1810.
170. WU J, RUSH TS III, HOTCHANDANI R et al.: Identification of potent and selective MMP-13 inhibitors. Bioorg. Med. Chem. Lett. (2005) 15(18):4105-4109.
171. ALVARO-GRACIA JM: Licofelone-clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis. Rheumatology (2004) 43(Suppl.1):i21-i25.
172. HAN Z, BOYLE DL, CHANG L et al.: c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J. Clin. Invest (2001) 108(1):73-81.
173. BENNETT BL, SASAKI DT, MURRAY BW et al.: SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. USA (2001) 98(24):13681-13686.
174. 2-terminal kinase in allergic airway inflammation and remodelling: effects of SP600125. Eur. J. Pharmacol. (2005) 506(3):273-283.
175. BESWICK P, BINGHAM S, BOUNTRA C et al.: Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. Lett. (2004) 14(21):5445-5448.
176. QUIRALTE J, DELGADO J, SAENZ DE SAN PB et al.: Safety of the new selective cyclooxygenase Type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs. Ann. Allergy Asthma Immunol. (2004) 93(4):360-364.
177. Bextra Label Updated with Boxed Warning Concerning Severe Skin Reactions and Warning Regarding Cardiovascular Risk: FDA (2004) Talk Paper T04-56.
178. European Medicines Agency announces regulatory action on COX-2 inhibitors: Public Statement EMEA (2005) 62757.
179. FITZGERALD GA: Coxibs and cardiovascular disease. N. Engl. J. Med. (2004) 351(17):1709-1711.
180. BANNWARTH B: Do selective cyclooxygenase-2 inhibitors have a future? Drug Saf. (2005) 28(3):183-189.
181. DOGNE JM, SUPURAN CT, PRATICO D: Adverse cardiovascular effects of the coxibs. J. Med. Chem. (2005) 48(7):2251-2257.
182. SOLOMON DH, AVORN J: Coxibs, science, and the public trust. Arch. Intern. Med. (2005) 165(2):158-160.
183. WU KK: Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin. Vasc. Med. (2003) 3(2):107-112.
184. NIEDERBERGER E, TEGEDER I, VETTER G et al.: Celecoxib loses its antiinflammatory efficacy at high doses through activation of NF-κB. FASEB J. (2001) 15(9):1622-1624.
185. CALABRESE EJ, BALDWIN LA: Hormesis: the dose-response revolution. Ann. Rev. Pharmacol. Toxicol. (2003) 43:175-197.
186. TEGEDER I, PFEILSCHIFTER J, GEISSLINGER G: Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. (2001) 15(12):2057-2072.
187. BRADLEY JD, DMITRIENKO AA, KIVITZ AJ et al.: A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. J. Rheumatol. (2005) 32(3):417-423.